Head-to-head evidence
MET-233i vs petrelintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
MET-233i
Developed by Pfizer
NCT07022977 · Phase 1 · completed
Participants were randomly assigned to MET233 or a matching placebo, with everyone blinded to the assignment, which is a sound safety-testing design. However, the trial's main measure was side-effect occurrence rather than weight loss, which was only a secondary measure, and results have not been posted yet.
petrelintide
Developed by Zealand Pharma and partners
NCT06662539 · Phase 2 · completed
The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MET-233i's landscape · petrelintide's landscape